Milan, Italy – September 14, 2006 – Newron Pharmaceuticals SpA, a research and development company focused on novel CNS therapies, today announces positive results from a preclinical study showing preemptive and palliative analgesic effects of ralfinamide against spontaneous chronic pain in a rodent model of neuropathy. The study was conducted by Professor Ze’ev Seltzer, Canada Senior Research Chair in Genetics of Pain, University of Toronto, and will be presented at the Fifth Congress of the European Federation of IASP Chapters (EFIC) Istanbul, Turkey, September 14, 2006.
